ISRCTN21188633已完成未知
Plasminogen shows rapid efficacy in treating patients with type I spinal muscular atrophy
Talengen Institute of Life Sciences0 个研究点目标入组 20 人开始时间: 2023年1月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The subjects were diagnosed with type I SMA with SMN gene mutation or non-5q SMA with mutation in the gene encoding immunoglobulin-binding protein 2 (IGHMBP2), according to genetic tests and clinical symptoms
排除标准
- •Patients receiving more than 16 hours of invasive ventilation per day
研究者
相似试验
已完成
不适用
Recombinant tissue Plasminogen Activator administration by retinal branch vein route for Central Retinal Vein Occlusion: a randomised conventional therapy controlled trialCentral Retinal Vein Occlusion (CRVO)Eye DiseasesISRCTN58543190Oogziekenhuis Rotterdam (OZR) (The Netherlands)48
已完成
2 期
Effect of treatment with tissue plasminogen activator in improving clinical status of patients with acute ischemic strokeIRCT201709049014N182Vice-chancellor for Research and Technology, Hamadan University of Medical Sciences40
招募中
不适用
t-PA trial for central retinal artery occlusioartery occlusionH341central retinal artery occlusionJPRN-jRCTs041190079Hayashi Atsushi20
进行中（未招募）
2 期
se of plasma of cured person to treat patient with severe covid-19Coronavirus infection, transfusion, C23, A00-B99, Coronavirus OC43, Human.A00-B99RBR-7f4mt9fHemocentro de Ribeirão Preto
已完成
不适用
Intraventricular infusion of rt-PA in severe intraventricular haemorrhage after aneurysmal subarachnoid haemorrhage. A randomised clinical trial.ISRCTN36786212niversity Medical Center Utrecht, Department of Neurology (The Netherlands)16